Tissue Array – Proteomics Consortium

The IMEx coronavirus interactome: an evolving map of Coronaviridae-host molecular interactions

By Hugh Dixon
May 19, 2021
No Comments

The present coronavirus illness of 2019 (COVID-19) pandemic, brought on by the extreme acute respiratory syndrome coronavirus (SARS-CoV)-2, has spurred a wave of analysis of practically unprecedented scale. Among the … Continue Reading →

Use of Hybrid Data-Dependent and -Independent Acquisition Spectral Libraries Empowers Dual-Proteome Profiling

By Hugh Dixon
April 16, 2021
No Comments

In the context of bacterial infections, it’s crucial that physiological responses could be studied in an built-in method, which means a simultaneous evaluation of each the host and the pathogen … Continue Reading →

$The identification of specific protein kinases as oncogenic drivers in a variety of cancer sorts, coupled with the clinical success of particular kinase-directed targeted therapies, has cemented the human kinome as an attractive source of 'actionable' targets for cancer remedy. However, 'mining' of the human kinome for precision oncology applications has yet to yield its full potential. This reflects a variety of points, including oncogenic kinase dysregulation at levels not detectable by genomic sequencing and the uncharacterized nature of a considerable fraction of the kinome. In addition, selective therapeutic targeting of specific kinases requires efficient mapping of total kinome space impacted by candidate small molecule medication. Fortunately, recent developments in proteomics strategies, particularly in mass spectrometry-based phosphoproteomics and kinomics, provide the necessary technology platforms to address these impediments. Moreover, initiatives such as the Clinical Proteomic Tumour Analysis Consortium have enabled the era, deposition and integration of genomic, transcriptomic and (phospho)proteomic data for many cancer sorts, providing unprecedented insights into oncogenic kinases and cancer cell signalling typically. These multi-omic data are identifying novel therapeutic targets, highlighting opportunities for drug re-purposing, and helping assign optimal therapies to specific tumour subtypes, heralding a new era of 'enhanced' precision oncology. This article is protected by copyright. All rights reserved.$

Human pores and skin is composed of the cell-rich dermis, the extracellular matrix (ECM) wealthy dermis, and the hypodermis.

By Hugh Dixon
April 11, 2021
No Comments

Within the dermis, a dense community of ECM proteins offers structural assist to the pores and skin and regulates a large variety of signaling pathways which govern cell proliferation and … Continue Reading →

Mass-spectrometry-based proteomic correlates of grade and stage reveal pathways and kinases associated with aggressive human cancers

By Hugh Dixon
March 11, 2021
No Comments

Proteomic signatures associated with medical measures of extra aggressive cancers may yield molecular clues as to illness drivers. Here, using the Clinical Proteomic Tumor Analysis Consortium (CPTAC) mass-spectrometry-based proteomics datasets, we outlined differentially expressed proteins and mRNAs … Continue Reading →

An Update on MRMAssayDB: A Comprehensive Resource for Targeted Proteomics Assays in the Community

By Hugh Dixon
March 11, 2021
No Comments

Precise multiplexed quantification of proteins in organic samples will be achieved by focused proteomics utilizing a number of or parallel response monitoring (MRM/PRM). Combined with inside requirements, the methodology achieves excellent repeatability … Continue Reading →

Myeloma Tissue Array With Normal Bone US Biomax

By Hugh Dixon
January 12, 2020
Comments Off on Myeloma Tissue Array With Normal Bone US Biomax

Catalog Number: 131-T291c Category: Tissue Array Supplier: US Biomax To order Myeloma Tissue Array With Normal Bone from US Biomax Contact info@proteomeconsortium.org Oxiselect Protein Carbonyl Immunoblot Deproteinizing Sample Preparation Kit … Continue Reading →

Lung Cancer Tissue Array With Normal US Biomax

By Hugh Dixon
January 12, 2020
Comments Off on Lung Cancer Tissue Array With Normal US Biomax

Catalog Number: 131-BC041115d Category: Tissue Array Supplier: US Biomax To order Lung Cancer Tissue Array With Normal from US Biomax Contact info@proteomeconsortium.org Biotin Conjugated Glycine Max Lectin Nad Nadh Quantitation … Continue Reading →

Malignant Melanoma Tissue Microarray US Biomax

By Hugh Dixon
January 12, 2020
Comments Off on Malignant Melanoma Tissue Microarray US Biomax

Catalog Number: 131-ME2082b Category: Tissue Array Supplier: US Biomax To order Malignant Melanoma Tissue Microarray from US Biomax Contact info@proteomeconsortium.org Fitc Conjugated Phytolacca Americana Transglutaminase Inhibitor Screening Nanolink Streptavidin Magnetic … Continue Reading →

Tf Activation Profiling Plate Array Signosis

By Hugh Dixon
January 12, 2020
Comments Off on Tf Activation Profiling Plate Array Signosis

Catalog Number: 350-FA-1001 Category: Tissue Array Supplier: Signosis To order Tf Activation Profiling Plate Array from Signosis Contact info@proteomeconsortium.org Elhghii Human Monkey IgG Anti Human Fap1 Pab Alexa Fluor 647 … Continue Reading →

Frozen Tissue Array 37 Diff. Breast Biochain

By Hugh Dixon
January 12, 2020
Comments Off on Frozen Tissue Array 37 Diff. Breast Biochain

Catalog Number: 36-T6235086-5 Category: Tissue Array Supplier: Biochain To order Frozen Tissue Array 37 Diff. Breast from Biochain Contact info@proteomeconsortium.org Mcdb 131 Medium Without L Glutamin Envelope Glycoprotein D Recombinant … Continue Reading →